300347 泰格医药
2025/03 - 三个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入1,564,144-5.79%6,603,1207,384,0397,085,4715,213,538
减:营业总成本1,421,4188.90%5,610,0485,554,1255,156,5443,637,765
    其中:营业成本1,094,3836.04%4,361,1074,535,5114,277,0082,942,883
               财务费用31,748-244.84%38,067(108,324)(158,124)(216,363)
               资产减值损失(3,524)-54.55%1,255(29,725)(2,416)(12,915)
公允价值变动收益(22,392)-275.58%(501,688)352,771535,8571,815,390
投资收益25,310-804.78%166,642338,175102,751312,283
    其中:对联营企业和合营企业的投资收益----31,271105,18339,76314,348
营业利润144,504-60.10%664,4192,486,9412,582,3993,696,967
利润总额143,625-60.36%664,4622,488,5332,585,3773,684,566
减:所得税费用33,644-32.43%216,630338,606313,652292,864
净利润109,981-64.81%447,8312,149,9272,271,7253,391,702
减:非控股权益(55,488)-171.60%42,688125,077265,173517,539
股东净利润165,469-29.61%405,1432,024,8502,006,5522,874,163

市场价值指针
每股收益 (元) *0.190-29.63%0.4702.3402.3203.310
每股派息 (元) *----0.3000.5680.5500.500
每股净资产 (元) *23.735-2.01%23.89824.10222.44720.774
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容